I guess they are looking to go the GcMaf route and retract it....
Too late !!
Dr. Yamamoto sold all his patents for GcMAF and related IP to an Israeli pharma company, Efranat [1], back in 2009. The company was able to raise some money [2] and conducted a PhI clinical trial [3] in humans [4].
Noakes' company started to produce and heavily promote what was claimed to be GcMAF in 2009/10. They never ran clinical trials (PhI-III) to show safety or efficiency, produced it in an unlicensed facility and used blood that wasn't safe for humans [5].
Refs:
1 http://efranat.com
2 Cancer treatment developer Efranat raises $4.5m - Globes
3 Safety Study of EF-022 ( Modified Vitamin D Binding Protein Macrophage Activator) in Subjects With Advanced Solid Tumors - Full Text View - ClinicalTrials.gov
4 https://www.linkedin.com/company/efranat-ltd-
5 Regulator warns against GcMAF made in unlicensed facility in Cambridgeshire